Industry Updates for the Psychedelics World

Psychedelics News

Industry

3 Oct 2023

atai Life Sciences Completes Phase 1 Study of Oral DMT

Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD)....

By Jason Najum

Industry

28 Sep 2023

Numinus Announces $10 Million Equity Program

Numinus has announced an at-the-market equity offering program that allows the company to issue and sell up to $10,000,000 (CAD) of common shares....

By Microdose NewsDesk

Industry

27 Sep 2023

FDA Accepts PharmaTher’s New Drug Application for KETARX™ (Ketamine)

The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of April 29, 2024....

By Microdose NewsDesk

Industry

25 Sep 2023

TheraPsil Unveils MDMA-Assisted Psychotherapy Training Program

Non-profit TheraPsil announces launching of MDMA therapy training program....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

21 Sep 2023

Seelos Therapeutics Announces Results from Phase II Depression Trial

Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide....

By Microdose NewsDesk

Industry

20 Sep 2023

Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations....

By Microdose NewsDesk

Industry

14 Sep 2023

MAPS Publishes Results of Successful Phase 3 Trial

In big industry news, MAPS has published the second part of its long-awaited Phase 3 trial of MDMA-assisted therapy for PTSD....

By Microdose NewsDesk

Industry

13 Sep 2023

The Longevity+DeSci Summit: Advancing the Frontiers of Longevity Science

The Microdose team attended the Longevity+DeSci Summit NYC, held on August 10-11, 2023. This groundbreaking conference brought together leaders in aging research, biotechnology, and decentralized science. Organized by the nonprofit...

By Microdose

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result